China’s Tencent Holdings has gained access to Nvidia’s Blackwell chips via a Tokyo-based cloud service provider operated, according to a report from Barron’s.
FDA placed a clinical hold on the proposed proof-of-concept clinical trial for Simufilam in tuberous sclerosis complex -related epilepsy earlier this week.
Mangoceuticals had also recently filed a trademark application for “MULTI-DAT” with the United States Patent and Trademark Office in a bid to expand into the digital asset space
Nvidia lagged megacap peers amid valuation concerns, China headwinds, and AI bubble fears, though pullback improved multiples and Wall Street remains bullish on long-term growth catalysts.
AI-driven memory demand pushed Micron’s revenue and margins sharply higher, giving it clearer growth visibility and stronger profitability than Oracle and Broadcom after earnings.
Legacy automakers GM and Ford have regained investor favor as EV demand cools, fundamentals strengthen, and Tesla’s momentum moderates amid valuation and affordability concerns.
Two major firms, Wedbush and Stifel, sharply raised their price targets, signaling stronger pricing trends and improving demand in the memory chip market.
Despite pressured fundamentals, SoundHound retains strong retail support, while analysts are optimistic about its long-term conversational AI opportunity.
ASTS stock surged to record highs despite delays, losses, and bloated valuation, as retail optimism clashes with analyst caution ahead of the crucial BlueBird 6 launch.
Rivian’s stock rebound is driven by faster delivery growth, expanding software revenue, and AI-led autonomy ambitions, though profitability, liquidity, and mass-market launches remain key risks.
Disney’s $1B OpenAI partnership offers strategic AI entry and content advantages, but investor sentiment remains muted as the stock trades sideways despite potential long-term benefits.
